CFO Eric Soyer Resigns to Accept Top Management Position of Publicly-Traded Biotech Company

World's Largest Prostate Cancer Clinic at University Hospital Hamburg-Eppendorf Expands Range of Treatment Options to Include Next-Generation Focal Therapy

1Q 2015 and Recent Operational Highlights Direct De Novo petition for Ablatherm HIFU submitted to the FDA in April 2015 ; Treatment-driven revenue from the HIFU division increased 17% year-over-year; Revenue for first quarter 2015 totaled EUR 6.2 million ( USD 6.9 million ); Canadian regulatory

Conference Call and Webcast Scheduled for 8:30 a.m. ET

2014 and Recent Operational Highlights Record revenue in 2014 of EUR 26.8 million ( USD 35.4 million ); 11% growth over the previous year; Full-year HIFU revenue increased 70% over 2013; Strong Cash position of EUR 12.1 million ( USD 14.7 million ) as of December 31, 2014 ; Filing Direct De Novo

Montreal Jewish General Hospital, Canada, Purchases Focal One HIFU Two Months After Health Canada Clearance

GE Healthcare Appointed Leading Coordinator of Consortium

Conference Call and Webcast Scheduled for 8:30 a.m. ET

FDA Meeting Held to Confirm Planned Approach

LYON, France , Feb. 26, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced a multi-national strategic OEM partnership with Quanta System, a leading manufacturer of medical lasers for surgical and other applications.